BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16918536)

  • 1. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
    Lowenstein H; Shah A; Chant A; Khan A
    Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
    Tenorio EP; Saavedra R
    Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
    Woods M; Guy R; Waldmann H; Glennie M; Alexander DR
    Cell Immunol; 1998 May; 185(2):101-13. PubMed ID: 9636688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rottlerin inhibits human T cell responses.
    Springael C; Thomas S; Rahmouni S; Vandamme A; Goldman M; Willems F; Vosters O
    Biochem Pharmacol; 2007 Feb; 73(4):515-25. PubMed ID: 17141738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
    Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
    Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
    Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
    Rowan WC; Hale G; Tite JP; Brett SJ
    Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-Limonene modulates T lymphocyte activity and viability.
    Lappas CM; Lappas NT
    Cell Immunol; 2012 Sep; 279(1):30-41. PubMed ID: 23059811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Campath-1H treatment of multiple sclerosis.
    Jones JL; Coles AJ
    Neurodegener Dis; 2008; 5(1):27-31. PubMed ID: 18075272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanosoma cruzi inhibits the expression of CD3, CD4, CD8, and IL-2R by mitogen-activated helper and cytotoxic human lymphocytes.
    Sztein MB; Cuna WR; Kierszenbaum F
    J Immunol; 1990 May; 144(9):3558-62. PubMed ID: 2139458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte activation in the lungs of SP-D null mice.
    Fisher JH; Larson J; Cool C; Dow SW
    Am J Respir Cell Mol Biol; 2002 Jul; 27(1):24-33. PubMed ID: 12091242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
    Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
    Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells.
    Croft M; Joseph SB; Miner KT
    J Immunol; 1997 Oct; 159(7):3257-65. PubMed ID: 9317124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.